Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing R&D Expenditure in Biotech and Pharma Companies
4.2.2 Rising Demand For Diagnostic Antibodies in Diagnosis of Diseases
4.3 Market Restraints
4.3.1 High Cost in Dvelepoment of Antibodies
4.3.2 Stringent Regulatory Policies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Monoclonal Antibodies
5.1.2 Polyclonal Antibodies
5.1.3 Others
5.2 By Application
5.2.1 Oncology Diagnosis
5.2.2 Hepatitis Diagnosis
5.2.3 Infectivous Disease Diagnosis
5.2.4 Others
5.3 By End-User
5.3.1 Diagnostic Laboratories
5.3.2 Hospitals
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Abcam plc
6.1.3 Abbott Laboratories
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Agilent Technologies, Inc.
6.1.6 Aytu BioScience, Inc
6.1.7 Boehringer Ingelheim International GmbH
6.1.8 Sanofi
6.1.9 Merck KGaA
6.1.10 Sartorius AG


7 MARKET OPPORTUNITIES AND FUTURE TRENDS